Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
P/B ratio for Protalix BioTherapeutics, Inc. (PLX)
P/B ratio as of 2023: 3.58
According to Protalix BioTherapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.58. At the end of 2022 the company had a P/B ratio of -6.24.
P/B ratio history for Protalix BioTherapeutics, Inc. from 1996 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.58 |
| 2022 | -6.24 |
| 2021 | -6.08 |
| 2020 | -3.91 |
| 2019 | -0.69 |
| 2018 | -0.87 |
| 2017 | -2.77 |
| 2016 | -45.31 |
| 2015 | 89.05 |
| 2014 | -30.74 |
| 2013 | -133.35 |
| 2012 | -1404.50 |
| 2011 | -160.03 |
| 2010 | -713.58 |
| 2009 | 320.70 |
| 2008 | 31.49 |
| 2007 | 3.59 |
| 2006 | 201.50 |
| 2005 | 8738.38 |
| 2004 | 759.10 |
| 2003 | 17.79 |
| 2002 | 4.03 |
| 2001 | 7.85 |
| 2000 | 5.60 |
| 1999 | 28.73 |
| 1998 | 30.61 |
| 1997 | 0.00 |
| 1996 | 0.00 |